Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer

Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of Transgene’s virus-based immunotherapies TG6002 and TG1050 in Greater China
information fournie par Boursorama 10/07/2018 à 13:00

Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of Transgene's virus-based immunotherapies TG6002 and TG1050 in Greater China

? Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares
? Deals give Tasly Biopharmaceuticals full control over Greater China development and commercial rights to the oncolytic virus T601 and the therapeutic vaccine T101
? Development of these immunotherapies for the Chinese market will benefit from the significant resources and capabilities of Tasly Biopharmaceuticals

The press release is available on www.trangene.fr

Valeurs associées

0,8740 EUR Euronext Paris +0,69%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.